AI Score

Unlock

argenx SE (ARGX)

AI Score

Unlock

607.80

26.86 (4.62%)

At close: Apr 14, 2025, 3:45 PM

4.62% (1D)

Bid	607.33
Market Cap	36.93B
Revenue (ttm)	2.15B
Net Income (ttm)	805.17M
EPS (ttm)	12.78
PE Ratio (ttm)	47.56
Forward PE	68.15
Analyst	Buy

Ask	607.93
Volume	546,097
Avg. Volume (20D)	338,814
Open	588.41
Previous Close	580.94
Day's Range	585.52 - 610.71
52-Week Range	352.77 - 678.21
Beta	0.20

About ARGX

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemp...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date May 18, 2017

Employees 1,599

Stock Exchange NASDAQ

Ticker Symbol ARGX

Website https://www.argenx.com

Full Company Profile

Analyst Forecast

According to 21 analyst ratings, the average rating for ARGX stock is "Buy." The 12-month stock price forecast is $700.5, which is an increase of 15.25% from the latest price.

Stock Forecasts

Next Earnings Release

argenx SE is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+3.01%

Argenx shares are trading higher after the company... Unlock content with Pro Subscription

5 months ago

+2.34%

Argenx shares are trading higher after Scotiabank upgraded the stock from Sector Perform to Sector Outperform and raised its price target from $439 to $715.

News

3 days ago · benzinga.com

FDA Approves Argenx's Vyvgart Hytrulo Prefilled Syringe For Self-Injection For At Home Use Setting

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE's ARGX Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase...

4 days ago · reuters.com

US FDA approves syringe version of Argenx's immune disorder drug

The U.S. Food and Drug Administration has approved a pre-filled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart, giving patients the more convenient option o...

1 week ago · seekingalpha.com

Stock Picks From Seeking Alpha's March 2025 New Analysts

In March, we welcomed 30 new analysts to Seeking Alpha, and in this article we are showcasing their stock picks and investment strategies. Our analysts covered a diverse set of industries—including IT...

2 weeks ago · zacks.com

JAZZ or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Jazz Pharmaceuticals (JAZZ) and argenex SE (ARGX). But which of these two companies is t...

3 weeks ago · zacks.com

Argenx (ARGX) Surges 4.1%: Is This an Indication of Further Gains?

Argenx (ARGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the...

1 month ago · seekingalpha.com

argenx SE (ARGX) Q4 2024 Earnings Call Transcript

argenx SE (NASDAQ:ARGX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Beth DelGiacco - Vice President, Corporate Communications and Investor Relations Tim Van Hau...

1 month ago · seekingalpha.com

argenx: Vyvgart's Sales Momentum Improves, Clinical Data Updates From A Key Competitor Imminent

argenx reported Q4 earnings today. Vyvgart's strong Q4 2024 performance, driven by the U.S. CIDP launch, positions it for continued growth with upcoming launches and approvals in Europe, Japan, and th...